Mon, March 14, 2022

Ed Arce Maintained (ABUS) at Strong Buy with Increased Target to $8.5 on, Mar 14th, 2022

Ed Arce of HC Wainwright & Co., Maintained "Arbutus Biopharma Corporation" (ABUS) at Strong Buy with Increased Target from $8 to $8.5 on, Mar 14th, 2022.

Ed has made no other calls on ABUS in the last 4 months.



There are 2 other peers that have a rating on ABUS. Out of the 2 peers that are also analyzing ABUS, 0 agree with Ed's Rating of Hold.



These are the ratings of the 2 analyists that currently disagree with Ed


  • Keay Nakae of "Chardan Capital" Maintained at Strong Buy with Increased Target to $6 on, Friday, March 4th, 2022
  • Dennis Ding of "Jefferies" Upgraded from Hold to Strong Buy and Increased Target to $5 on, Wednesday, February 2nd, 2022